BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AtCor Medical Pty Ltd Announces $3.2 Million Pharmaceutical Clinical Trial Contract


10/8/2012 9:16:49 AM

ITASCA, IL--(Marketwire - October 08, 2012) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central aortic pressures and arterial stiffness noninvasively, today announced that it has signed a contract to supply SphygmoCor® systems and clinical trial support services to a major pharmaceutical company. Systems will be placed at sites throughout Europe and North America. The value of the contract is approximately $3.2 million.

Duncan Ross, CEO of AtCor Medical, said, "We are delighted to have secured this significant contract. This, together with the $1.1 million pharmaceutical contract announced in August, represents a very good start to our financial year."

"This contract is with an existing client that we have worked with for many years," Ross said. "The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs. It is encouraging that AtCor's gold standard technology, data management and support services are being validated through repeat business from the pharmaceutical sector."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure and arterial stiffness noninvasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,900 SphygmoCor® systems are currently in use worldwide at major medical centers, research institutions, in physicians' offices and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 600 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States and Europe. For further information, please visit our web site at www.atcormedical.com.




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES